contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


remedy-waiting-aw2-sales-figures-positive-view

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Atte Riikola

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Great trailer and the hype started nicely. Hopefully, the Remedyverse is hammered with a customizable sledgehammer into the black hole at the beginning of the trailer, and after Max Payne, we get something other than smoke orcs in dim lighting. Hopefully, the gameplay is polished to perfection here, and the story is left in the background. Remedy knows how to develop a great world, but for my taste, it gets so out of hand that at some point, I lose interest. Especially in Control. The AW2 story kept my interest, but the scariest part was the clunky gameplay in action sequences. Resonant was a positive surprise, but I wasn’t fully enthusiastic because it’s set in the Remedyverse’s Control world and isn’t its own separate story.

I will probably play this. Like most Remedy games. But compared to my expectations, the predominant feeling was disappointment. Perhaps most visually, which is on the same level as AW2. Whereas Control → AW Remastered → AW2 was a clear and big change, it doesn’t seem to be that way from AW2 → Control Resonant. The gameplay also makes me wonder; I’m more of a fan of shooting than melee attacks. From its trailer, it’s weaker for me than AW2. It’s hard to believe the story will be better than AW2. Somehow it still feels like a heavy thought to jump into the same Remedy-verse again, but that’s just a personal opinion. The same shadow smoke creatures are encountered from one release to another. Remedy would need the ability to create something new, but it’s difficult for a small game studio to succeed at that, as we’ve already seen. Additionally, AW2 gave me some gray hairs in the form of DLC, similar to Control. For example, I couldn’t bring myself to finish them in Control or AW2. I don’t see much added value for the player in them; they become available too late. The story has already ended; I don’t want to reopen it with any side plot half a year later, with gameplay mechanics I’ve already forgotten. I won’t be buying it anymore. I’ve been waiting for Max Payne for a long time, having played them through when I was young, but now I’m starting to fear that Remedy won’t be able to take the game to a new level, as seems to be happening with Resonant. Mainly, I’m afraid that Remedy’s game engine will ruin what Max Payne once was. Ultimately, I believe this will remain primarily a fan product; it’s hard to believe it will achieve anything close to AW2’s sales level. But an investor can certainly make money with this once the anticipation game begins.

In my opinion, this doesn’t really matter to an investor whether the game is ultimately good or not. The hype train has now started big time and the game will be released in a year, so this looks like a pretty good buy the rumors sell the news-style momentum investment. So the playbook is to go boldly back to buying by Monday at the latest, and then in late 2026, one can reconsider whether to exit the investment and whether the game looks like it’s going to be anything when more gameplay footage is seen, or if one dares to own the stock even after the release of Control 2. Of course, it would have been smarter to anticipate the Game Awards by taking a speculative ownership in Remedy, but there’s still time to get in. The share price, by all accounts, will be significantly higher than it is now closer to the release, as Max Payne is also just around the corner. My longer-term view on Remedy is still bearish, but it does seem like an opportunity is opening up to take easy profits. My own thoughts, not an investment recommendation, make your own investment decisions carefully, etc.

Yes, the hype from Asmongold (4+ million followers) and other big YouTubers/social media influencers really does have an effect on generating interest in the game. And the trailer certainly looked great visually.

Even Asmongold praised the trailer, so it can only be top-notch  But seriously, it certainly looks good, and gameplay will surely determine its success - the framework is in order. A bold move to revamp the concept, but it can also bring in new fans if it succeeds.

That trailer was really nice to watch. It seems to have already gathered a lot of viewers and positive comments

That was indeed a great first trailer. You can immediately see that these main games are what Remedy truly invests in, and then there are the Firebreaks and other side projects… The game mechanics are changing significantly, as (it seems) the gunplay is being left out. Quite risky given Remedy’s background, but hopefully it’s the right solution.

Remedy Entertainment

Remedy's Q3 report did not yet provide any information on preliminary sales figures for Alan Wake 2. However, the game's excellent reception by critics and players alike creates a strong foundation for good sales success and also strengthens Remedy's long-term prospects in many ways.

<p>Remedy's Q3 report did not yet provide any information on preliminary sales figures for Alan Wake 2. However, the game's excellent reception by critics and players alike creates a strong foundation for good sales success and also strengthens Remedy's long-term prospects in many ways. The market is already pricing in good success of future games, for which the reception of AW2 also provided good grounds. As such, we will follow the sales performance of AW2 with a positive view on the stock.</p> 

	2022	23e	24e
Revenue	43.6	31.8	72.5
growth-%	-2.5 %	-27.0 %	127.8 %
EBIT (adj.)	-0.6	-20.3	19.9
EBIT-% (adj.)	-1.3 %	-63.6 %	27.5 %
EPS (adj.)	-0.13	-1.21	1.18
Dividend	0.10	0.10	0.10
Dividend %	0.5 %	0.6 %	0.6 %
P/E (adj.)	neg.	neg.	14.0
EV/EBITDA	126.5	neg.	7.5

Remedy: Waiting for AW2 sales figures with a positive view

Login required

Key Estimate Figures31.10.2023

Forum discussions